Therapeutic Solutions International (TSOI) 10-Q 17 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 17, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-54554
Entity Registrant Name	Therapeutic Solutions International, Inc.
Entity Central Index Key	0001419051
Entity Tax Identification Number	45-1226465
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	701 Wild Rose Lane
Entity Address, City or Town	Elk City
Entity Address, State or Province	ID
Entity Address, Postal Zip Code	83525
City Area Code	(760)
Local Phone Number	295-7208
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		2,608,288,008

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 94,246	$ 94,036
Restricted cash	11,003	10,223
Accounts receivable	42,382	16,613
Inventory	44,943	39,817
Prepaid expenses and other current assets	332,015	959,307
Total current assets	524,589	1,119,996
Property and equipment, net	354,135	284,024
Right-of-use asset	15,071	34,184
Other assets	3,298,465	277,571
Total assets	4,192,260	1,715,775
Current liabilities:
Accounts payable	363,984	394,035
Accounts payable-related parties	7,239	9,791
Accrued expenses and other current liabilities	552,240	487,208
Lease liability	12,918	25,374
Notes payable, current portion	4,638	4,071
Convertible notes payable, net of discount of $210,242 and $225,800, at September 30, 2022 and December 31, 2021, respectively	79,008	79,200
Notes payable-related parties, net	982,203	965,211
Derivative liabilities	392,561	531,525
Total current liabilities	2,394,791	2,496,415
LONG TERM LIABILITIES
Notes payable, net of current portion	11,641	15,532
Lease liability, net of current portion	2,153	8,810
TOTAL LIABILITIES	2,408,585	2,520,757
Commitments and contingencies
Shareholders’ Equity (Deficit):
Preferred stock, $ 0.001 par value; 5,000,000 shares authorized, 2 shares and 0 shares issued and outstanding at September 30, 2022 and December 31, 2021 Respectively
Common stock, $ 0.001 par value; 3,500,000,000 shares authorized; 2,588,063,537 and 2,311,123,860 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively.	2,588,064	2,311,125
Additional paid-in capital	15,948,999	10,899,139
Subscription receivable	(21,000)	(21,000)
Accumulated deficit	(16,732,388)	(13,994,246)
Total shareholders’ equity (deficit)	1,783,675	(804,982)
Total liabilities and shareholders’ equity (deficit)	$ 4,192,260	$ 1,715,775

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Debt instrument, unamortized discount, current	$ 210,242	$ 225,800
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	2	0
Preferred stock, shares outstanding	2	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	3,500,000,000	3,500,000,000
Common stock, shares, issued	2,588,063,537	2,311,123,860
Common stock, shares, outstanding	2,588,063,537	2,311,123,860

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Net sales	$ 74,541	$ 57,291	$ 198,188	$ 101,796
Cost of goods sold	8,790	12,431	33,437	27,598
Gross profit	65,751	44,860	164,751	74,198
Operating expenses:
General and administrative	204,838	31,271	388,561	96,722
Salaries, wages, and related costs	110,108	83,968	336,926	319,198
Consulting fees	88,158	107,514	317,284	224,844
Legal and professional fees	106,795	492,295	266,158	636,193
Research and development	275,071	31,815	1,177,123	183,597
Total operating expenses	784,970	746,863	2,486,052	1,460,554
Loss from operations	(719,219)	(702,003)	(2,321,301)	(1,386,356)
Other income (expense):
Loss on derivative liabilities	(26,867)	(45,006)	(136,583)	(477,559)
Change in fair value of derivative liabilities	(32,205)	53,624	233,303	624,376
Interest expense	(167,371)	(121,414)	(512,761)	(399,425)
Total other income (expense)	(226,443)	(112,796)	(416,041)	(252,608)
LOSS BEFORE PROVISION FOR INCOME TAXES	(945,662)	(814,799)	(2,737,342)	(1,638,964)
Provision for income taxes	800		800
Net loss	$ (946,462)	$ (814,799)	$ (2,738,142)	$ (1,638,964)
Net loss per share - basic and diluted	$ 0	$ 0	$ 0	$ 0
Weighted average shares outstanding - basic and diluted	2,565,663,048	2,267,469,428	2,501,116,667	2,253,155,062

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) (Unaudited) - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Shares To Be Issued [Member]	Subscription Receivable [Member]	Retained Earnings [Member]	Total
Beginning balance at Dec. 31, 2020		$ 2,233,742	$ 7,041,960		$ (21,000)	$ (11,032,801)	$ (1,778,099)
Beginning balance, shares at Dec. 31, 2020		2,233,741,391
Common stock issued for services		$ 8,500	512,900	36,821			558,221
Common stock issued for services, shares		8,500,000
Common stock issued for prepaid fees		$ 7,500	539,950				547,450
Common stock issued for prepaid fees, shares		7,500,000
Common stock issued for salaries		$ 8,342	231,458				239,800
Common stock issued for accrued salaries, shares		8,341,723
Common stock issued for cash		$ 4,850	280,649				285,499
Common stock issued for cash, shares		4,850,075
Common stock issued for land development		$ 1,500	57,400				58,900
Common stock issued for land development, shares		1,500,000
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		$ 10,499	292,660				303,159
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares		10,499,263
Relief of derivative liabilities			302,365				302,365
Net loss						(1,638,964)	(1,638,964)
Ending balance at Sep. 30, 2021		$ 2,274,933	9,259,342	36,821	(21,000)	(12,671,765)	(1,121,669)
Ending balance, shares at Sep. 30, 2021		2,274,932,452
Beginning balance at Dec. 31, 2020		$ 2,233,742	7,041,960		(21,000)	(11,032,801)	(1,778,099)
Beginning balance, shares at Dec. 31, 2020		2,233,741,391
Ending balance at Dec. 31, 2021		$ 2,311,125	10,899,139		(21,000)	(13,994,246)	(804,982)
Ending balance, shares at Dec. 31, 2021		2,311,123,860
Beginning balance at Jun. 30, 2021		$ 2,259,522	8,321,915		(21,000)	(11,856,966)	(1,296,529)
Beginning balance, shares at Jun. 30, 2021		2,259,521,681
Common stock issued for services		$ 5,000	345,000	36,821			386,821
Common stock issued for services, shares		5,000,000
Common stock issued for prepaid fees		$ 4,500	343,450				347,950
Common stock issued for prepaid fees, shares		4,500,000
Common stock issued for salaries		$ 797	40,003				40,800
Common stock issued for accrued salaries, shares		796,875
Common stock issued for cash		$ 1,278	58,722				60,000
Common stock issued for cash, shares		1,278,396
Common stock issued for land development		$ 1,000	34,700				35,700
Common stock issued for land development, shares		1,000,000
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		$ 2,836	53,874				56,710
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares		2,835,500
Relief of derivative liabilities			61,678				61,678
Net loss						(814,799)	(814,799)
Ending balance at Sep. 30, 2021		$ 2,274,933	9,259,342	36,821	(21,000)	(12,671,765)	(1,121,669)
Ending balance, shares at Sep. 30, 2021		2,274,932,452
Beginning balance at Dec. 31, 2021		$ 2,311,125	10,899,139		(21,000)	(13,994,246)	(804,982)
Beginning balance, shares at Dec. 31, 2021		2,311,123,860
Common stock issued for services		$ 25,303	482,775				508,078
Common stock issued for services, shares		25,302,577
Common stock issued for prepaid fees		$ 11,000	231,320				242,320
Common stock issued for prepaid fees, shares		11,000,000
Common stock issued for salaries		$ 1,034	28,965				29,999
Common stock issued for accrued salaries, shares		1,034,482
Common stock issued for cash		$ 44,500	400,500				445,000
Common stock issued for cash, shares		44,500,000
Common stock issued for land development		$ 4,000	46,400				50,400
Common stock issued for land development, shares		4,000,000
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		$ 41,700	901,732				943,432
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares		41,700,228
Relief of derivative liabilities
Net loss						(2,738,142)	(2,738,142)
Common stock issued for license		$ 149,402	2,958,168				3,107,570
Common stock issued for license, shares		149,402,390
Issuance of preferred stock
Issuance of preferred stock, shares	2
Ending balance at Sep. 30, 2022		$ 2,588,064	15,948,999		(21,000)	(16,732,388)	1,783,675
Ending balance, shares at Sep. 30, 2022	2	2,588,063,537
Beginning balance at Jun. 30, 2022		$ 2,552,228	15,467,138		(21,000)	(15,785,926)	2,212,440
Beginning balance, shares at Jun. 30, 2022		2,552,228,460
Common stock issued for services		$ 9,303	91,575				100,878
Common stock issued for services, shares		9,302,577
Common stock issued for prepaid fees		$ 5,000	88,500				93,500
Common stock issued for prepaid fees, shares		5,000,000
Common stock issued for land development		$ 4,000	46,400				50,400
Common stock issued for land development, shares
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		$ 17,533	255,386				272,919
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares		17,532,500
Net loss						(946,462)	(946,462)
Issuance of preferred stock
Issuance of preferred stock, shares	2
Ending balance at Sep. 30, 2022		$ 2,588,064	$ 15,948,999		$ (21,000)	$ (16,732,388)	$ 1,783,675
Ending balance, shares at Sep. 30, 2022	2	2,588,063,537

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		69 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022
Cash flows from operating activities
Net loss	$ (946,462)	$ (814,799)	$ (2,738,142)	$ (1,638,964)	$ 16,700,000
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation to consultants			311,078	416,321
Stock-based compensation to related parties			197,000	141,900
Loss on derivative liabilities	26,867	45,006	136,583	477,559
Change in fair value of derivative liabilities	32,205	(53,624)	(233,303)	(624,376)
Amortization of prepaid stock-based compensation			868,089	91,646
Amortization of debt discount			461,058	353,320
Patent amortization			191,192	4,943
Depreciation			3,489	4,051
Changes in operating assets and liabilities:
Accounts receivable			(25,769)	(19,047)
Inventory			(5,126)	(56,005)
Prepaid expenses and other current assets			73,807	88,789
Right-of-use asset			19,113	18,531
Accounts payable			(30,051)	59,178
Accounts payable - related parties			(2,552)	42
Accrued expenses and other current liabilities			139,405	132,549
Lease liability			(19,113)	(18,531)
Net cash used in operating activities			(653,242)	(568,094)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment				(260,565)
Purchase of license			(200,000)
Deposits				4,015
Net cash used in investing activities			(200,000)	(256,550)
Cash flows from financing activities
Payments on notes payable to related party			(2,444)	(3,503)
Proceeds from convertible notes payable			415,000	353,750
Payments on notes payable			(3,324)	(969)
Proceeds from sale of common stock			445,000	285,499
Net cash provided by financing activities			854,232	634,777
Net increase (decrease) in cash, cash equivalents and restricted cash			990	(189,867)
Cash, cash equivalents and restricted cash at beginning of period			104,259	262,349
Cash, cash equivalents and restricted cash at end of period	105,249	72,482	105,249	72,482	105,249
Supplemental cash flow information:
Cash paid for interest			2,357	2,311
Cash paid for income taxes			800	800
Non-cash investing and financing transactions:
Original issuance discount on convertible notes payable			30,500	22,250
Debt discount recorded in connection with derivative liability			415,000	353,750
Common stock issued in conversion of convertible notes payable and interest			943,431	605,525
Property and equipment purchased with note payable				21,671
Common stock issued for prepaid fees			242,320	547,450
Common stock issued for accrued salaries			29,999	239,800
Accrued interest added to principal			19,436	19,434
Common stock issued for license			3,107,570
Common stock issued for land development			50,400	58,900
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:
Cash and cash equivalents	94,246	62,259	94,246	62,259	94,246
Restricted cash	11,003	10,223	11,003	10,223	11,003
Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows:	$ 105,249	$ 72,482	$ 105,249	$ 72,482	$ 105,249

Organization and Business Descr

Organization and Business Description	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Description	Note 1 – Organization and Business Description Therapeutic Solutions International, Inc. (“TSI” or the “Company”) was organized August 6, 2007 Friendly Auto Dealers, Inc., Business Description Currently, the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions. TSOI is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, lung pathologies, and for daily health. Cellular Division The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability. Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells. On March 4, 2021 the Company received an IND Serial # 27377 for a clinical trial of 10 patients with CTE. On August 4th, 2021, the Company announced clearance from the Food and Drug Administration (FDA) to initiate a Phase III pivotal trial for registration of the Company’s JadiCell™ universal donor stem cell as a treatment for COVID-19 associated lung failure under IND # 19757. In previous studies the Company has demonstrated the superior activity of JadiCell™ to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%. In addition, the Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs™ resulted in enhanced activity of a type of immunological cell called “natural killer” cells, otherwise known as “NK cells.” The Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body’s NK cells. Most recently the Company announced filing of a patent for a new hybrid cell created by the Company capable of training the immune system to kill blood vessels feeding cancer but sparing healthy blood vessels. These discoveries are an extension of previous findings from the Company showing that StemVacs is capable of suppressing new blood vessel production. On May 9, 2022, the Company filed an Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell™ Universal Donor Adult Stem Cells under IND Serial # 28508. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 Management does not expect existing cash as of September 30, 2022, to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumed the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of September 30, 2022, the Company has incurred losses totaling $ 16.7

Basis of presentation and signi

Basis of presentation and significant accounting policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of presentation and significant accounting policies	Note 2 – Basis of presentation and significant accounting policies Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented. Revenue Recognition The Company recognizes revenue in accordance with ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. Returns. Wholesale policies: Delivery. Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 Inspection of Goods & Rejection. Risk of Loss. Retail policies of e-commerce: Shipping. Out of Stock. Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0 0 Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items. Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2022 and 2021, as disclosed in Note 8 containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $ 392,561 531,525 Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of September 30, 2022 and December 31, 2021, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the nine months ended September 30, 2022: Schedule of Change in Derivative Liability Balance, December 31, 2021 $ 531,525 Issuance of new derivative liabilities 576,592 Conversions (482,253 ) Change in fair market value of derivative liabilities (233,303 ) Balance, September 30, 2022 $ 392,561 Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates. Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss. Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of September 30, 2022 and 2021, a total of 211,919,728 286,251,995 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the nine months ended September 30, 2022 and 2021 was $ 3,489 4,051 Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the nine months ended September 30, 2022 and 2021 was $ 191,192 4,943 Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $ 1,177,123 183,597 Income Taxes The Company accounts for income taxes under ASC 740 “Income Taxes,” “Accounting for Income Taxes” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares. Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $ 15,071 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 Recent Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of the reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018-13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted, including in an interim period for which financial statements have not been issued or made available for issuance. The Company has evaluated the impact of adoption of this ASU and determined that it will have no significant impact on its consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 eliminated certain exceptions and changed guidance on other matters. The exceptions relate to the allocation of income taxes in separate company financial statements, tax accounting for equity method investments and accounting for income taxes when the interim period year-to-date loss exceeds the anticipated full year loss. Changes relate to the accounting for franchise taxes that are income-based and non-income-based, determining if a step up in tax basis is part of a business combination or if it is a separate transaction, when enacted tax law changes should be included in the annual effective tax rate computation, and the allocation of taxes in separate company financial statements to a legal entity that is not subject to income tax. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the potential impact but does not believe there will be an impact of the adoption of this standard on its results of operations, financial position and cash flows and related disclosures.

Restricted cash

Restricted cash	9 Months Ended
	Sep. 30, 2022
Cash and Cash Equivalents [Abstract]
Restricted cash	Note 3 – Restricted cash Included in current assets is a $ 10,000 0.6 This certificate matures on June 17, 2023, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011

Prepaid expense and other curre

Prepaid expense and other current assets	9 Months Ended
	Sep. 30, 2022
Prepaid Expense And Other Current Assets
Prepaid expense and other current assets	Note 4 – Prepaid expense and other current assets Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets September 30, 2022 December 31, 2021 Prepaid consulting $ 239,646 $ 930,893 Insurance 1,717 987 Prepaid costs 90,652 27,427 Total $ 332,015 $ 959,307 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022

Fixed assets

Fixed assets	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Fixed assets	Note 5 – Fixed assets Fixed assets consist of the following: Schedule of Fixed Assets September 30, 2022 December 31, 2021 Land $ 308,823 $ 235,223 Vehicles 50,514 50,514 Computer hardware 6,135 5,935 Office furniture and equipment 7,912 7,912 Shipping and other equipment 1,575 1,575 Total 374,959 301,159 Accumulated depreciation (20,824 ) (17,135 ) Property and equipment, net $ 354,135 $ 284,024 Depreciation expense was $ 3,489 4,051

Other assets

Other assets	9 Months Ended
	Sep. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other assets	Note 6 – Other assets Other assets consist of the following: Schedule of Other Assets September 30, 2022 December 31, 2021 Prepaid consulting $ 13,189 $ 108,673 Deposit 39,823 39,823 Regulatory assets/Patent rights 200,000 - Licenses, net 3,045,453 129,075 Total $ 3,298,465 $ 277,571 As of June 1, 2019, we entered into a license agreement, which will be amortized over the life of the Patent. The Patent expires December 31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of CTE (Chronic Traumatic Encephalopathy), and TBI (Traumatic Brain Injury). The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2. On February 9, 2021, the Company issued a Convertible Promissory Note (CPN) to JadiCell LLC that was never fully executed while the parties worked to finalize the agreement that resulted in an Exclusive Patent License Agreement (EPLA) being executed on 9/15/2021. Finally, a Settlement Agreement was entered into on February 23, 2022. On February 23, 2022, we issued 149,402,390 0.0208 3,107,570 December 31, 2032 10 five years 200,000 1.8 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: Schedule of Net Licenses September 30, 2022 December 31, 2021 Licenses $ 3,261,122 $ 153,552 Accumulated amortization (215,669 ) (24,477 ) Licenses, net $ 3,045,453 $ 129,075 Amortization expense for the nine months ended September 30, 2022 and 2021 was $ 191,192 4,943

Notes Payable-Related Party

Notes Payable-Related Party	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Notes Payable-Related Party	Note 7 - Notes Payable-Related Party At September 30, 2022 and December 31, 2021, the Company has unsecured interest-bearing demand notes outstanding to certain officers and directors amounting to $ 982,203 $965,211 12,956 12,956 251,000 0.004 0.005

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 8 – Convertible Notes Payable At various times during the nine months ended September 30, 2022, the Company entered into convertible promissory notes with principal amounts totaling $ 445,500 415,000 30,500 10 12 January 1, 2023 to September 27, 2023 The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150% 224,973,061 Derivative liabilities These convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes in the derivative liability fair value are reported in operating results each reporting period. For the notes issued during the nine months ended September 30, 2022, the Company valued the conversion feature on the date of issuance resulting in an initial liability of $ 576,592 161,592 0.0064 0.0143 0.0153 0.0272 0 148 216 0.48 4.16 one year THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 During the nine months ended September 30, 2022, convertible notes with principal and accrued interest balances totaling $ 620,051 41,700,228 25,009 0.0063 0.016 0.010 0.026 0 63 191 0.51 4.08 0.44 0.50 On September 30, 2022, the derivative liabilities on the remaining convertible notes were revalued at $ 392,561 233,303 0.0064 0.013 0 92 158 4.05 0.52 0.99 The Company amortizes the discounts over the term of the convertible promissory notes using the straight-line method which is similar to the effective interest method. During the nine months ended September 30, 2022 and 2021, the Company amortized $ 461,058 353,320 210,242 amortized through September 2023

Equity

Equity	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Equity	Note 9 – Equity Our authorized capital stock consists of an aggregate of 3,505,000,000 3,500,000,000 0.001 5,000,000 2,588,063,537 2 In 2021, we issued 4,850,075 285,500 In 2021, we issued 21,000,000 858,900 In 2021, we issued 8,341,723 239,799 In 2021, we issued 1,500,000 58,900 In 2021, we issued 21,690,671 1,019,014 In 2022, we issued 44,500,000 445,000 In 2022, we issued 25,302,577 508,078 In 2022, we issued 1,034,482 29,999 In 2022, we issued 149,402,390 3,107,570 In 2022, we issued 41,700,228 595,042 In 2022, we issued 11,000,000 242,320 In 2022, we issued 4,000,000 50,400 On August 4, 2022, the Board of Directors designated “Series A Preferred Stock” and caused to be filed a Certificate of Designation pursuant to NRS 78.1955 with the State of Nevada, and upon approval the Board has issued One (1) share of Series A Preferred Stock to Thomas E. Ichim, and One (1) share of Series A Preferred Stock to Timothy G. Dixon. The Holder of the Series A Preferred Stock shall be entitled to vote on all matters subject to a vote or written consent of the holders of the Corporation’s Common Stock, and on all such matters, the share of Series A Preferred Stock shall be entitled to that number of votes equal to the number of votes that all issued and outstanding shares of Common Stock and all other securities of the Corporation are entitled to, as of any such date of determination, on a fully diluted basis, plus One Million (1,000,000) votes, it being the intention that the Holder(s) of the Series A Preferred Stock shall have effective voting control of the Corporation, on a fully diluted basis. The Holder(s) of the Series A Preferred Stock shall vote together with the holders of Common Stock as a single class. On August 9, 2022, we issued 2 0.001 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022

Subsequent events

Subsequent events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent events	Note 10 – Subsequent events On October 5, 2022, we issued 110,000 .0122 On October 7, 2022, we issued 5,322,581 33,000 On October 11, 2022, we issued 8,014,113 49,687.50 On November 2, 2022, we issued 3,000,000 .0099 On November 2, 2022, we issued 3,777,777 .0099 In accordance with ASC 855, the Company has analyzed its operations subsequent to November 17, 2022 through the date these financial statements were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 11 – Commitments and Contingencies Effective March 1, 2020, the Company entered into a fifth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists of approximately 1,700 36 April 30, 2023 Total rent expense for the nine months is $ 18,783 The lease will expire in 2023 5 Future minimum lease payments as of December 31, 2022, are as follows: Schedule of Future Minimum Lease Payments For the year ending December 31, 2022 $ 6,249 2023 $ 8,612 As of March 25, 2022, we entered into an asset transfer and license agreement, which will be amortized over the life of the agreement. The agreement is for five years . The Company has made an initial payment of $ 200,000 . Within six months, the Company will make a second payment of $ 1.8 million. The Company has not made the payment yet. This has not affected the agreement.

Basis of presentation and sig_2

Basis of presentation and significant accounting policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. Returns. Wholesale policies: Delivery. Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 Inspection of Goods & Rejection. Risk of Loss. Retail policies of e-commerce: Shipping. Out of Stock.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0 0
Inventories	Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items.
Derivative Liabilities	Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2022 and 2021, as disclosed in Note 8 containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $ 392,561 531,525
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of September 30, 2022 and December 31, 2021, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the nine months ended September 30, 2022: Schedule of Change in Derivative Liability Balance, December 31, 2021 $ 531,525 Issuance of new derivative liabilities 576,592 Conversions (482,253 ) Change in fair market value of derivative liabilities (233,303 ) Balance, September 30, 2022 $ 392,561
Use of Estimates	Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.
Comprehensive Loss	Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss.
Net Loss Per Share	Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of September 30, 2022 and 2021, a total of 211,919,728 286,251,995
Depreciation and Amortization	Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the nine months ended September 30, 2022 and 2021 was $ 3,489 4,051
Intangible Assets	Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the nine months ended September 30, 2022 and 2021 was $ 191,192 4,943
Long-lived Assets	Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.
Research and Development	Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $ 1,177,123 183,597
Income Taxes	Income Taxes The Company accounts for income taxes under ASC 740 “Income Taxes,” “Accounting for Income Taxes” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.”
Stock-Based Compensation	Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares.
Leases	Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $ 15,071
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of the reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018-13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted, including in an interim period for which financial statements have not been issued or made available for issuance. The Company has evaluated the impact of adoption of this ASU and determined that it will have no significant impact on its consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 eliminated certain exceptions and changed guidance on other matters. The exceptions relate to the allocation of income taxes in separate company financial statements, tax accounting for equity method investments and accounting for income taxes when the interim period year-to-date loss exceeds the anticipated full year loss. Changes relate to the accounting for franchise taxes that are income-based and non-income-based, determining if a step up in tax basis is part of a business combination or if it is a separate transaction, when enacted tax law changes should be included in the annual effective tax rate computation, and the allocation of taxes in separate company financial statements to a legal entity that is not subject to income tax. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the potential impact but does not believe there will be an impact of the adoption of this standard on its results of operations, financial position and cash flows and related disclosures.

Basis of presentation and sig_3

Basis of presentation and significant accounting policies (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Schedule of Change in Derivative Liability	The following is the change in derivative liability for the nine months ended September 30, 2022: Schedule of Change in Derivative Liability Balance, December 31, 2021 $ 531,525 Issuance of new derivative liabilities 576,592 Conversions (482,253 ) Change in fair market value of derivative liabilities (233,303 ) Balance, September 30, 2022 $ 392,561

Prepaid expense and other cur_2

Prepaid expense and other current assets (Tables)	9 Months Ended
	Sep. 30, 2022
Prepaid Expense And Other Current Assets
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets September 30, 2022 December 31, 2021 Prepaid consulting $ 239,646 $ 930,893 Insurance 1,717 987 Prepaid costs 90,652 27,427 Total $ 332,015 $ 959,307

Fixed assets (Tables)

Fixed assets (Tables)	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following: Schedule of Fixed Assets September 30, 2022 December 31, 2021 Land $ 308,823 $ 235,223 Vehicles 50,514 50,514 Computer hardware 6,135 5,935 Office furniture and equipment 7,912 7,912 Shipping and other equipment 1,575 1,575 Total 374,959 301,159 Accumulated depreciation (20,824 ) (17,135 ) Property and equipment, net $ 354,135 $ 284,024

Other assets (Tables)

Other assets (Tables)	9 Months Ended
	Sep. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Assets	Other assets consist of the following: Schedule of Other Assets September 30, 2022 December 31, 2021 Prepaid consulting $ 13,189 $ 108,673 Deposit 39,823 39,823 Regulatory assets/Patent rights 200,000 - Licenses, net 3,045,453 129,075 Total $ 3,298,465 $ 277,571
Schedule of Net Licenses	Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: Schedule of Net Licenses September 30, 2022 December 31, 2021 Licenses $ 3,261,122 $ 153,552 Accumulated amortization (215,669 ) (24,477 ) Licenses, net $ 3,045,453 $ 129,075

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments	Future minimum lease payments as of December 31, 2022, are as follows: Schedule of Future Minimum Lease Payments For the year ending December 31, 2022 $ 6,249 2023 $ 8,612

Organization and Business Des_2

Organization and Business Description (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		69 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Entity incorporation date			Aug. 06, 2007
Entity information, former legal or registered name			Friendly Auto Dealers, Inc.,
Net loss	$ (946,462)	$ (814,799)	$ (2,738,142)	$ (1,638,964)	$ 16,700,000

Schedule of Change in Derivativ

Schedule of Change in Derivative Liability (Details)	9 Months Ended
	Sep. 30, 2022 USD ($)
Accounting Policies [Abstract]
Beginning Balance	$ 531,525
Issuance of new derivative liabilities	576,592
Conversions to paid-in capital	(482,253)
Change in fair market value of derivative liabilities	(233,303)
Ending Balance	$ 392,561

Basis of presentation and sig_4

Basis of presentation and significant accounting policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Payments description			Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail
Cash, FDIC insured amount	$ 0	$ 0	$ 0	$ 0
Derivative liabilities	392,561		$ 392,561		$ 531,525
Antidilutive securities excluded from computation of earnings per share			211,919,728	286,251,995
Depreciation expense			$ 3,489	$ 4,051
Amortization of intangible assets			191,192	4,943
Research and development expense	275,071	$ 31,815	1,177,123	$ 183,597
Right-of-use asset	15,071		15,071		$ 34,184
Lease liability	15,071		15,071
Maximum [Member]
Property, Plant and Equipment [Line Items]
Cash, FDIC insured amount	$ 250,000		$ 250,000

Restricted cash (Details Narrat

Restricted cash (Details Narrative)	9 Months Ended
	Sep. 30, 2022 USD ($)
Cash and Cash Equivalents [Abstract]
Restricted cash and non-cash equivalents	$ 10,000
Annual interest rate	0.60%
Restricted cash description	This certificate matures on June 17, 2023, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011

Schedule of Prepaid Expenses an

Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Prepaid Expense And Other Current Assets
Prepaid consulting	$ 239,646	$ 930,893
Insurance	1,717	987
Prepaid costs	90,652	27,427
Total	$ 332,015	$ 959,307

Schedule of Fixed Assets (Detai

Schedule of Fixed Assets (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total	$ 374,959	$ 301,159
Accumulated depreciation	(20,824)	(17,135)
Property and equipment, net	354,135	284,024
Land [Member]
Property, Plant and Equipment [Line Items]
Total	308,823	235,223
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Total	50,514	50,514
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	6,135	5,935
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	7,912	7,912
Shipping and Other Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	$ 1,575	$ 1,575

Fixed assets (Details Narrative

Fixed assets (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 3,489	$ 4,051

Schedule of Other Assets (Detai

Schedule of Other Assets (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid consulting	$ 13,189	$ 108,673
Deposit	39,823	39,823
Regulatory assets/Patent rights	200,000
Licenses, net	3,045,453	129,075
Total	$ 3,298,465	$ 277,571

Schedule of Net Licenses (Detai

Schedule of Net Licenses (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Licenses	$ 3,261,122	$ 153,552
Accumulated amortization	(215,669)	(24,477)
Licenses, net	$ 3,045,453	$ 129,075

Other assets (Details Narrative

Other assets (Details Narrative) - USD ($)			3 Months Ended	9 Months Ended
	Mar. 25, 2022	Feb. 23, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Number of shares issuance value			$ 60,000	$ 445,000	$ 285,499
Payment to acquire license				200,000
Amortization of intangible assets				$ 191,192	$ 4,943
Common Stock [Member]
Number of shares issuance			1,278,396	44,500,000	4,850,075
Number of shares issuance value			$ 1,278	$ 44,500	$ 4,850
Exclusive patent license agreement [Member] | Convertible Promissory Note [Member]
Patent expires agreement date		Dec. 31, 2032
Amortized useful life		10 years
Exclusive patent license agreement [Member] | Convertible Promissory Note [Member] | Common Stock [Member]
Number of shares issuance		149,402,390
Share price		$ 0.0208
Number of shares issuance value		$ 3,107,570
Assets Transfer and License Agreement [Member]
Amortized life of agreement	5 years
Assets Transfer and License Agreement [Member] | Initial Payment [Member]
Payment to acquire license	$ 200,000
Assets Transfer and License Agreement [Member] | Second Payment [Member]
Payment to acquire license	$ 1,800,000

Notes Payable-Related Party (De

Notes Payable-Related Party (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021
Debt Instrument [Line Items]
Notes payable related party	$ 982,203	$ 965,211
Officers and Directors [Member]
Debt Instrument [Line Items]
Notes payable related party	982,203	$ 965,211
Accrued interest	12,956		$ 12,956
Debt conversion amount	$ 251,000
Officers and Directors [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt conversion price	$ 0.004
Officers and Directors [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt conversion price	$ 0.005

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Debt Instrument [Line Items]
Proceeds from convertible debt			$ 415,000	$ 353,750
Derivative liabilities	$ 392,561		392,561		$ 531,525
Interest expenses	167,371	$ 121,414	512,761	399,425
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt discount	210,242		$ 210,242
Debt maturity date description			amortized through September 2023
Interest expenses			$ 461,058	$ 353,320
Convertible Promissory Note [Member]
Debt Instrument [Line Items]
Debt principal amount	445,500		445,500
Proceeds from convertible debt			415,000
Debt discount	$ 30,500		$ 30,500
Debt maturity date description			January 1, 2023 to September 27, 2023
Debt conversion description			The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%
Common shares reserve for future issuance	224,973,061		224,973,061
Derivative issuance liability			$ 576,592
Loss on derivative liability			$ 161,592
Convertible Promissory Note [Member] | Measurement Input, Expected Term [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term			1 year
Convertible Promissory Note [Member] | Derivative [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0		0
Convertible Promissory Note [Member] | Minimum [Member]
Debt Instrument [Line Items]
Interest rate percentage	10%		10%
Convertible Promissory Note [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.48		0.48
Convertible Promissory Note [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.0064		0.0064
Convertible Promissory Note [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.0153		0.0153
Convertible Promissory Note [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	148		148
Convertible Promissory Note [Member] | Maximum [Member]
Debt Instrument [Line Items]
Interest rate percentage	12%		12%
Convertible Promissory Note [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	4.16		4.16
Convertible Promissory Note [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.0143		0.0143
Convertible Promissory Note [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.0272		0.0272
Convertible Promissory Note [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	216		216
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible notes payable	$ 620,051		$ 620,051
Debt conversion of convertible shares			41,700,228
Gain on derivative liabilities			$ 25,009
Convertible Notes Payable [Member] | Derivative [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0		0
Convertible Notes Payable [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.0063		0.0063
Convertible Notes Payable [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.010		0.010
Convertible Notes Payable [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	63		63
Convertible Notes Payable [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.51		0.51
Convertible Notes Payable [Member] | Minimum [Member] | Derivative [Member] | Measurement Input, Expected Term [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term			5 months 8 days
Convertible Notes Payable [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.016		0.016
Convertible Notes Payable [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.026		0.026
Convertible Notes Payable [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	191		191
Convertible Notes Payable [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	4.08		4.08
Convertible Notes Payable [Member] | Maximum [Member] | Derivative [Member] | Measurement Input, Expected Term [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term			6 months
Remaining Convertible Notes [Member]
Debt Instrument [Line Items]
Gain on derivative liabilities			$ 233,303
Derivative liabilities	$ 392,561		$ 392,561
Remaining Convertible Notes [Member] | Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.013		0.013
Remaining Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0		0
Remaining Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	4.05		4.05
Remaining Convertible Notes [Member] | Measurement Input, Exercise Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.0064		0.0064
Remaining Convertible Notes [Member] | Minimum [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	92		92
Remaining Convertible Notes [Member] | Minimum [Member] | Measurement Input, Expected Term [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term			6 months 7 days
Remaining Convertible Notes [Member] | Maximum [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	158		158
Remaining Convertible Notes [Member] | Maximum [Member] | Measurement Input, Expected Term [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term			11 months 26 days

Equity (Details Narrative)

Equity (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Aug. 09, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Capital stock, authorized	3,505,000,000		3,505,000,000
Common stock, shares authorized	3,500,000,000		3,500,000,000		3,500,000,000
Common stock, par value	$ 0.001		$ 0.001		$ 0.001
Preferred stock, shares authorized	5,000,000		5,000,000		5,000,000
Common stock, shares issued	2,588,063,537		2,588,063,537		2,311,123,860
Common stock, shares outstanding	2,588,063,537		2,588,063,537		2,311,123,860
Preferred stock, shares issued	2		2		0	2
Preferred stock, shares outstanding	2		2		0
Number of shares issued		$ 60,000	$ 445,000	$ 285,499
Common stock issued for conversion of notes	$ 272,919	$ 56,710	$ 943,432	$ 303,159
Preferred stock, par value	$ 0.001		$ 0.001		$ 0.001	$ 0.001
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued, shares		1,278,396	44,500,000	4,850,075
Number of shares issued		$ 1,278	$ 44,500	$ 4,850
Common stock issued for conversion of notes, shares	17,532,500	2,835,500	41,700,228	10,499,263
Common stock issued for conversion of notes	$ 17,533	$ 2,836	$ 41,700	$ 10,499
Common Stock [Member] | Convertible Notes Payable [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued for conversion of notes, shares			41,700,228		21,690,671
Common stock issued for conversion of notes			$ 595,042		$ 1,019,014
Common Stock [Member] | Land Development [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued, shares			4,000,000		1,500,000
Number of shares issued			$ 50,400		$ 58,900
Common Stock [Member] | Salaries [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued, shares			1,034,482		8,341,723
Number of shares issued			$ 29,999		$ 239,799
Common Stock [Member] | License [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued, shares			149,402,390
Number of shares issued			$ 3,107,570
Common Stock [Member] | Prepaid fees [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued, shares			11,000,000
Number of shares issued			$ 242,320
Common Stock [Member] | Consulting Services [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued, shares			25,302,577		21,000,000
Number of shares issued			$ 508,078		$ 858,900
Common Stock [Member] | Private Placement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued, shares			44,500,000		4,850,075
Number of shares issued			$ 445,000		$ 285,500

Subsequent events (Details Narr

Subsequent events (Details Narrative) - USD ($)					3 Months Ended		9 Months Ended		12 Months Ended
	Nov. 02, 2022	Oct. 11, 2022	Oct. 07, 2022	Oct. 05, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Subsequent Event [Line Items]
Conversion of common stock					$ 272,919	$ 56,710	$ 943,432	$ 303,159
Common Stock [Member]
Subsequent Event [Line Items]
Shares issued for consulting service					9,302,577	5,000,000	25,302,577	8,500,000
Conversion of common stock, shares					17,532,500	2,835,500	41,700,228	10,499,263
Conversion of common stock					$ 17,533	$ 2,836	$ 41,700	$ 10,499
Common stock issued for cash, shares						1,278,396	44,500,000	4,850,075
Common Stock [Member] | Salaries [Member]
Subsequent Event [Line Items]
Common stock issued for cash, shares							1,034,482		8,341,723
Consulting Services [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Common stock issued for cash, shares							25,302,577		21,000,000
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Conversion of common stock, shares		8,014,113	5,322,581
Conversion of common stock		$ 49,687.50	$ 33,000
Subsequent Event [Member] | Common Stock [Member] | Salaries [Member]
Subsequent Event [Line Items]
Share issued price per share	$ 0.0099
Common stock issued for cash, shares	3,777,777
Subsequent Event [Member] | Consulting Services [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Shares issued for consulting service	3,000,000			110,000
Share issued price per share	$ 0.0099			$ 0.0122

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Details)	Sep. 30, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2022	$ 6,249
2023	$ 8,612

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)		9 Months Ended
	Mar. 25, 2022 USD ($)	Sep. 30, 2022 USD ($) ft²	Sep. 30, 2021 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Payments to Acquire Intangible Assets		$ 200,000
Assets Transfer and License Agreement [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Amortized life of agreement	5 years
Assets Transfer and License Agreement [Member] | Initial Payment [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Payments to Acquire Intangible Assets	$ 200,000
Assets Transfer and License Agreement [Member] | Second Payment [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Payments to Acquire Intangible Assets	$ 1,800,000
Effective March 1, 2020 [Member] | Lease Agreement [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Area of land | ft²		1,700
Lease contract term		36 months
Lease expiration date		Apr. 30, 2023
Rental expense		$ 18,783
Lease description		The lease will expire in 2023
Operating lease discount rate		5%